ClinicalTrials.gg
CompletedNCT01399580Updated Oct 25, 2013

A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy

A Phase 2 interventional study of Atrasentan and Placebo in Chronic Kidney Disease and Diabetic Nephropathy, sponsored by AbbVie (prior sponsor, Abbott). Completed at 28 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-10-25.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Renal Insufficiency, Chronic by AbbVie — none open to participants now, none under way, none of them phase 3. Renal Insufficiency, Chronic · AbbVie.

Enrollment
9th of 12
48 · median 62
Started
2011
with 6 others
Phase 2
4 of 19
none open now
Registered
13th of 19
by date

Among the 19 studies in Renal Insufficiency, Chronic by AbbVie, this one is the 9th largest by enrollment of the 12 interventional ones that give a count, is one of 7 that started in 2011, is one of 4 in phase 2, and was the 13th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

None of the 19 studies in Renal Insufficiency, Chronic by AbbVie is open now. The open studies under Renal Insufficiency, Chronic, anywhere →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Renal Insufficiency, Chronic by AbbVie as a file.
02

Study summary

Prospective, Randomized, Double-Blind, Parallel Design, Placebo-Controlled Multicenter Study. The study objectives are to evaluate efficacy and safety, including thoracic bioimpedance, of once daily administration of atrasentan tablets (high dose and low dose) compared to placebo in type 2 diabetic subjects with nephropathy who are receiving the maximum tolerated labeled daily dose of a RAS inhibitor.

03

Conditions studied

  • Chronic Kidney Disease
  • Diabetic Nephropathy

Keywords

  • endothelin receptor antagonists
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is greater than or equal to 18 years old.
  2. Subject has type 2 diabetes and has been treated with at least one anti-hyperglycemic medication within the 12 months prior to the Screening Period.
  3. Subject is currently receiving an angiotensin converting enzyme inhibitor (ACEi) or Angiotensin II receptor blocker (ARB) (Renin Angiotensin System (RAS) inhibitor).
  4. If female, subject is not breastfeeding and is not pregnant (verified by negative serum pregnancy test prior to the Treatment Period). Subject is not of , defined as for at least one year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) or is of childbearing potential and practicing one of the approved methods of as defined in the Clinical Trial Protocol. Contraception must be used during the study and for 4 weeks after the last dose of study drug.
  5. For entry into the Run-in Period the subject must satisfy the following criteria based on the Screening laboratory values:

    • Estimated (eGFR) greater than or equal to 30 and less than or equal to 75 mL/min/1.73m\^2 by the Epidemiology Collaboration (EPI) formula
    • Urinary Albumin to Creatinine Ratio (UACR) greater than or equal to 300 and less than or equal to 3500 mg/g as determined by the geometric mean of the two morning void urine specimens obtained at the Screening visit
    • Serum albumin greater than or equal to 3.0 g/dL
    • B-Type Natriuretic Peptide (BNP) less than or equal to 200 pg/mL
    • Negative serum pregnancy test for female subjects
    • Systolic Blood Pressure (SBP) greater than or equal to 110 mmHg and less than or equal to 180 mmHg
    • Glucosylated () less than or equal to 12%
  6. For entry into the Treatment Period the subject must satisfy the following criteria based on the last visit of the Run-in Period laboratory values:

    • Renin Angiotensin System (RAS) inhibitor at maximum tolerated labeled dose for the previous 4 weeks with no adjustment of dose
    • Diuretic at any dose unless medically (with the exception of loop diuretics greater than or equal to 120 mg QD of furosemide or greater than or equal to 3.0 mg QD of bumetanide or greater than or equal to 150 mg QD of ethacrynic acid or greater than or equal to 60 mg QD of torasemide)
    • UACR ≥ 200 mg/g as determined by the median of the three morning void urine specimens obtained prior to the Week -1 visit
    • Systolic Blood Pressure (SBP) greater than or equal to 110 mmHg and less than or equal to 160 mmHg
    • Serum Potassium less than or equal to 5.5 mEq/L
    • Negative serum pregnancy test for female subjects

Exclusion criteria

Exclusion Criteria:

  1. Patient has a history of moderate or severe edema, facial edema unrelated to trauma, or a history of myxedema in the prior 6 months to Screening.
  2. Subject is receiving loop diuretics greater than or equal to 120 mg QD of furosemide or greater than or equal to 3.0 mg QD of bumetanide or greater than or equal to 150 mg QD of ethacrynic acid or greater than or equal to 60 mg QD of torasemide.
  3. Subject has a history of pulmonary edema.
  4. Subject has a history of pulmonary hypertension, or any lung diseases requiring oxygen therapy (i.e., , emphysema, pulmonary fibrosis).
  5. Subject has a history of orthostatic hypotension within the past 6 months as defined by the presence of a supine-to-standing blood pressure decrease greater than or equal to 20 mmHg systolic or greater than or equal to 10 mmHg diastolic within 3 minutes of standing.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Placebo comparator
    Group A - Placebo QD

    Drug: Placebo

  • Active comparator
    Group B - Low dose Atrasentan QD

    Drug: Atrasentan

  • Active comparator
    Group C - High dose Atrasentan QD

    Drug: Atrasentan

Interventions

  • Subjects will take two tablets daily of either low dose Atrasentan QD or high dose Atrasentan QD for 8 weeks during the treatment period.

    Also known as: ABT-627

  • DrugPlacebo

    Subjects will take two tablets daily of placebo QD for 8 weeks during the treatment period.

06

What researchers measure

Primary outcomes

  1. Change from baseline to each post-baseline visit up to Week 8 in log-transformed Urinary Albumin to Creatinine Ratio (UACR)

    Time frame: Every two weeks for 8 weeks

Secondary outcomes

  1. Change from baseline to each post baseline measure for estimated glomerular filtration rate (eGFR)

    Time frame: Every two weeks for 8 weeks

  2. The change from baseline to each post-baseline assessment of thoracic bioimpedance

    Time frame: Treatment Day 1, Week 1, 2, 4, 6, 8 and 30 days post-treatment

07

Study locations

28 sites
  • Site Reference ID/Investigator# 58144
    Phoenix, Arizona 85032, United States
  • Site Reference ID/Investigator# 71034
    Tempe, Arizona 85284, United States
  • Site Reference ID/Investigator# 56927
    Azusa, California 91702, United States
  • Site Reference ID/Investigator# 70793
    Azusa, California 91702, United States
  • Site Reference ID/Investigator# 64027
    Chula Vista, California 91910, United States
  • Site Reference ID/Investigator# 54120
    Concord, California 94520, United States
  • Site Reference ID/Investigator# 64026
    La Mesa, California 91942, United States
  • Site Reference ID/Investigator# 70173
    Los Angeles, California 90048, United States
  • Site Reference ID/Investigator# 54121
    Denver, Colorado 80209, United States
  • Site Reference ID/Investigator# 56924
    Boynton Beach, Florida 33472, United States
  • Site Reference ID/Investigator# 56642
    Hollywood, Florida 33021, United States
  • Site Reference ID/Investigator# 68986
    Augusta, Georgia 30901, United States
  • Site Reference ID/Investigator# 56644
    Chicago, Illinois 60611, United States
  • Site Reference ID/Investigator# 54129
    Baton Rouge, Louisiana 70808, United States
  • Site Reference ID/Investigator# 68982
    Pontiac, Michigan 48341, United States
  • Site Reference ID/Investigator# 64023
    Albany, New York 12206, United States
  • Site Reference ID/Investigator# 55543
    Flushing, New York 11355, United States
  • Site Reference ID/Investigator# 54164
    Fargo, North Dakota 58103, United States
  • Site Reference ID/Investigator# 58147
    Willoughby Hills, Ohio 44094, United States
  • Site Reference ID/Investigator# 54123
    Bethlehem, Pennsylvania 18017, United States
  • Site Reference ID/Investigator# 61742
    Pittsburg, Pennsylvania 15224, United States
  • Site Reference ID/Investigator# 54132
    Chattanooga, Tennessee 37408, United States
  • Site Reference ID/Investigator# 54108
    Dallas, Texas 75231, United States
  • Site Reference ID/Investigator# 54126
    Greenville, Texas 75402, United States
  • Site Reference ID/Investigator# 58153
    Houston, Texas 77024, United States
  • Site Reference ID/Investigator# 54110
    Houston, Texas 77099, United States
  • Site Reference ID/Investigator# 54116
    North Richland Hills, Texas 76180, United States
  • Site Reference ID/Investigator# 54173
    Silverdale, Washington 98383, United States
08

References and documents

Publications

  • Lin CW, Mostafa NM, L Andress D, J Brennan J, Klein CE, Awni WM. Relationship Between Atrasentan Concentrations and Urinary Albumin to Creatinine Ratio in Western and Japanese Patients With Diabetic Nephropathy. Clin Ther. 2018 Feb;40(2):242-251. doi: 10.1016/j.clinthera.2017.07.011. Epub 2017 Jul 27. PubMed 28756065 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2011
First posted
Jul 22, 2011
Start
Aug 2011
Primary completionActual
Sep 2012
CompletionActual
Sep 2012
Results delay requested
Sep 25, 2013
Last update
Oct 25, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01399580
Responsible party
Sponsor
First posted
Jul 22, 2011
Start date
Aug 2011
Primary completion
Sep 2012
Completion
Sep 2012
Last update
Oct 25, 2013

Study contacts

Blai Coll, MD
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atrasentan

Start the discussion